Bacteria-Based ‘Cocktails’ Show Promise in Boosting Cancer Immunotherapy
A novel approach utilizing customized bacterial mixtures could revolutionize bladder cancer treatment, offering a potentially more effective and affordable alternative to existing therapies.
A team of researchers at Penn State has pioneered a new strategy in the fight against cancer, focusing on the power of the body’s own immune system. Their work, detailed in a paper published December 2 in Nature Communications, centers around creating customized mixtures of bacterial products – dubbed “microbial product cocktails” or MPCs – to significantly enhance the immune response against cancerous cells, specifically in bladder cancer. Early testing on patient tumor samples and in animal models has yielded promising results.
The Evolution of Bacterial Immunotherapy
For decades, doctors have recognized a link between bacterial infections and cancer regression. As early as the 1800s, observations suggested a connection, but it wasn’t until 1976 that this understanding translated into a clinical treatment: bacillus Calmette-Guérin (BCG) immunotherapy. This involves introducing live bacteria into a patient’s body to stimulate an immune response against cancer cells. While BCG remains the only approved bacterial immunotherapy for bladder cancer, its effectiveness is limited, and optimization is crucial.
“This type of immunotherapy, which relies on a single bacterial type, works for only a portion of patients,” explained Pak Kin Wong, professor of biomedical engineering and of mechanical engineering at Penn State, and lead author of the study. “We now know that our immune system interacts with thousands of different kinds of bacteria every day, which opens many new possibilities and can help make treatments more effective.”
Introducing Microbial Product Cocktails (MPCs)
The Penn State team’s innovation lies in moving beyond live bacteria to utilize microbial product cocktails (MPCs). Instead of introducing whole, live bacteria, MPC immunotherapy employs products derived from bacteria. This approach offers several advantages. Researchers gain greater control over the treatment process and can safely test a wider range of bacterial combinations without the risk of causing illness.
To determine the optimal mixtures, the team developed an artificial intelligence (AI) model that analyzes and optimizes both the composition and dosage of microbial products. These AI-optimized cocktails are then tested on tumor organoids – miniature tumors grown from a patient’s own tumor tissue – to assess their ability to activate the patient’s immune response. This personalized approach allows for tailored treatment plans.
Personalized Medicine and Cost-Effectiveness
The potential for personalized medicine is a key strength of the MPC immunotherapy approach. By tailoring the bacterial cocktail to each patient’s specific needs, researchers aim to maximize treatment efficacy. Furthermore, the team believes this new method could be as affordable, or even more affordable, than current cancer treatment options.
“The ability to personalize treatment while potentially lowering costs is a significant step forward,” noted a senior official familiar with the research.
The researchers are optimistic about the future of MPC immunotherapy and its potential to expand beyond bladder cancer to treat other types of malignancies. Further research and clinical trials will be necessary to fully validate these findings and bring this promising new therapy to patients.
